ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
First Claim
Patent Images
1. An antibody that binds a complement C1s protein, wherein the antibody is selected from the group consisting of:
- an antibody comprising a complementarity-determining region (CDR) having an amino acid sequence selected from the group consisting of SEQ ID NO;
1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, and SEQ ID NO;
6;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
9, SEQ ID NO;
10, SEQ ID NO;
11, SEQ ID NO;
12, SEQ ID NO;
13, and SEQ ID NO;
14;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
17, SEQ ID NO;
18, SEQ ID NO;
19, SEQ ID NO;
20, SEQ ID NO;
21, and SEQ ID NO;
22;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
25, SEQ ID NO;
26, SEQ ID NO;
27, SEQ ID NO;
28, SEQ ID NO;
29, and SEQ ID NO;
30;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
33, SEQ ID NO;
34, SEQ ID NO;
35, SEQ ID NO;
36, SEQ ID NO;
37, and SEQ ID NO;
38;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
41, SEQ ID NO;
42, SEQ ID NO;
43, SEQ ID NO;
44, SEQ ID NO;
45, and SEQ ID NO;
46;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
49, SEQ ID NO;
50, SEQ ID NO;
51, SEQ ID NO;
52, SEQ ID NO;
53, and SEQ ID NO;
54;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
57, SEQ ID NO;
58, SEQ ID NO;
59, SEQ ID NO;
60, SEQ ID NO;
61, and SEQ ID NO;
62;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
65, SEQ ID NO;
66, SEQ ID NO;
67, SEQ ID NO;
68, SEQ ID NO;
69, and SEQ ID NO;
70;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
73, SEQ ID NO;
74, SEQ ID NO;
75, SEQ ID NO;
76, SEQ ID NO;
77, and SEQ ID NO;
78;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
81, SEQ ID NO;
82, SEQ ID NO;
83, SEQ ID NO;
84, SEQ ID NO;
85, and SEQ ID NO;
86;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
89, SEQ ID NO;
90, SEQ ID NO;
91, SEQ ID NO;
92, SEQ ID NO;
93, and SEQ ID NO;
94;
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
97, SEQ ID NO;
98, SEQ ID NO;
99, SEQ ID NO;
100, SEQ ID NO;
101, and SEQ ID NO;
102; and
an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
105, SEQ ID NO;
106, SEQ ID NO;
107, SEQ ID NO;
108, SEQ ID NO;
109, and SEQ ID NO;
110.
2 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
4 Citations
51 Claims
-
1. An antibody that binds a complement C1s protein, wherein the antibody is selected from the group consisting of:
-
an antibody comprising a complementarity-determining region (CDR) having an amino acid sequence selected from the group consisting of SEQ ID NO;
1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, and SEQ ID NO;
6;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
9, SEQ ID NO;
10, SEQ ID NO;
11, SEQ ID NO;
12, SEQ ID NO;
13, and SEQ ID NO;
14;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
17, SEQ ID NO;
18, SEQ ID NO;
19, SEQ ID NO;
20, SEQ ID NO;
21, and SEQ ID NO;
22;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
25, SEQ ID NO;
26, SEQ ID NO;
27, SEQ ID NO;
28, SEQ ID NO;
29, and SEQ ID NO;
30;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
33, SEQ ID NO;
34, SEQ ID NO;
35, SEQ ID NO;
36, SEQ ID NO;
37, and SEQ ID NO;
38;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
41, SEQ ID NO;
42, SEQ ID NO;
43, SEQ ID NO;
44, SEQ ID NO;
45, and SEQ ID NO;
46;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
49, SEQ ID NO;
50, SEQ ID NO;
51, SEQ ID NO;
52, SEQ ID NO;
53, and SEQ ID NO;
54;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
57, SEQ ID NO;
58, SEQ ID NO;
59, SEQ ID NO;
60, SEQ ID NO;
61, and SEQ ID NO;
62;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
65, SEQ ID NO;
66, SEQ ID NO;
67, SEQ ID NO;
68, SEQ ID NO;
69, and SEQ ID NO;
70;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
73, SEQ ID NO;
74, SEQ ID NO;
75, SEQ ID NO;
76, SEQ ID NO;
77, and SEQ ID NO;
78;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
81, SEQ ID NO;
82, SEQ ID NO;
83, SEQ ID NO;
84, SEQ ID NO;
85, and SEQ ID NO;
86;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
89, SEQ ID NO;
90, SEQ ID NO;
91, SEQ ID NO;
92, SEQ ID NO;
93, and SEQ ID NO;
94;an antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
97, SEQ ID NO;
98, SEQ ID NO;
99, SEQ ID NO;
100, SEQ ID NO;
101, and SEQ ID NO;
102; andan antibody comprising a CDR having an amino acid sequence selected from the group consisting of SEQ ID NO;
105, SEQ ID NO;
106, SEQ ID NO;
107, SEQ ID NO;
108, SEQ ID NO;
109, and SEQ ID NO;
110. - View Dependent Claims (2, 3, 10, 13, 14, 17, 19, 20, 23, 25, 26, 41, 42, 44, 45, 50)
-
-
4-7. -7. (canceled)
-
8. An antibody that binds a human complement C1s protein, wherein the antibody is selected from the group consisting of:
-
an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
7 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
8;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
15 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
16;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
23 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
24;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
31 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
32;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
39 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
40;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
47 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
48;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
55 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
56;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
63 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
64;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
71 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
72;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
79 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
80;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
87 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
88;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
95 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
96;an antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
103 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
104; andan antibody that specifically binds an epitope within the complement C1s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
111 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
112. - View Dependent Claims (9)
-
-
11-12. -12. (canceled)
-
15-16. -16. (canceled)
-
18. (canceled)
-
21-22. -22. (canceled)
-
24. (canceled)
-
27-40. -40. (canceled)
-
43. (canceled)
-
46-49. -49. (canceled)
-
51-82. -82. (canceled)
Specification